Numbers

The Numbers

Daqo is a balance-sheet story trading like a cash-burn story. The polysilicon cycle has wiped out earnings — revenue collapsed from $4.6B (FY22) to $665M (FY25), and operating income flipped from +$3.0B to -$270M. Yet the company still sits on $1.94B of cash with zero debt and $5.9B of book equity. With the stock at ~$19 today, the market cap of roughly $1.29B is below the company's cash balance — enterprise value is negative at -$655M, meaning investors are pricing roughly $0.66 of recovery on every $1 of net cash. The stock trades at ~0.22x book ($87.43/share), a level usually reserved for businesses the market expects to liquidate. The single number that will rerate or derate this stock is the polysilicon ASP: every $1/kg above cash cost on 200kt+ of capacity is roughly $200M of incremental EBITDA. Until that price recovers, the question is not valuation — it is how fast the cash pile erodes.

A. Snapshot

B. Quality Scorecard

The balance sheet is the only thing keeping this name investable. Take the cash away and there is nothing in the income statement worth paying for — Daqo is structurally a low-cost producer in a commodity that is currently selling below cash cost industry-wide.

C. Forensic Health Flags

The Piotroski 3/9 confirms the fundamental weakness: profitability and efficiency legs score zero. Altman Z at 2.64 sits in the grey zone — the balance sheet keeps it from distress territory, but negative earnings drag it below safety. The Beneish M-Score flag is mechanical (receivables-to-sales distortion during a revenue collapse) rather than a manipulation signal, but it warrants monitoring.

D. Revenue & Earnings Power — 15-Year View

The 15-year view reveals this is Daqo's second cycle through negative margins — the 2012-2013 polysilicon crash nearly killed the company. The 2021-2022 supercycle was real but temporary. By FY2024-FY2025 the company was back to negative gross and operating margins, a pattern that rhymes with the prior downturn but at vastly larger scale.

E. Unit Economics — The Chart That Matters Most

FY2025 ASP was ~$5.25/kg against production cost of $6.61/kg — a negative spread of -$1.36/kg that widened from FY2024. Higher volume alone cannot fix earnings; the Phase 5 expansion lifted nameplate capacity to 305,000 MT, but that scale is a burden when industry oversupply pushes prices below cost.

F. The Collapse, in Quarters

Q1 2026 is the most alarming data point on this page: revenue of $26.7M is a ~95% drop from peak quarterly revenue, ~78% below Q1 2025, and well below the (already depressed) Q4 2025 print of $222M. The Q1 2026 operating loss of $151M has resurrected the cash-burn narrative that Q3-Q4 2025 had been narrowing. The late-2025 sequential bounce did not hold. This is the data point most likely driving recent share price weakness.

G. Cash Conversion — Are the Earnings Real?

Cash conversion runs hot during good years (CFO/NI of 1.0-2.5x, helped by D&A and working capital releases) and flatters the headline in bad years too — FY25 operating cash flow was positive $50M against a $171M net loss because $240M of D&A is non-cash. The truer signal is FCF: -$917M cumulative across FY24-FY25 even as capex was throttled from $1.2B to $173M. Trailing five-year FCF was only 39.7% of Daqo-attributable net income because the company poured cash into Phase 5 expansion just as the cycle rolled over. Capex now runs below depreciation — protects cash but signals no capacity expansion is funded from current operations.

H. Capital Allocation

Capital allocation has been capacity-first. The only meaningful return of capital came in FY22-FY23 — $611M of buybacks executed at average prices well above today's quote. Since FY24, with cash flow negative, management has frozen buybacks and stopped paying down debt (debt is already zero). No common dividend appears in the cash-flow data. Stock-based compensation has compressed to $56M in FY25 — manageable, but a cumulative ~$580M of SBC since FY18 has diluted the share count against only $616M of repurchases.

I. Balance-Sheet Health

This is where the bull case lives. Daqo carries no interest-bearing debt, $1.94B of cash, and $5.92B of equity against a $1.29B market cap. Book value per share has held above $63 for four consecutive years — even through two years of losses — because retained earnings from FY21-22 ($2.5B) absorbed all subsequent damage. The risk: FY24 cash dropped $935M, FY25 dropped another $161M; another year of similar burn would breach $1B. And consolidated cash is not fully available to the listed entity — the Xinjiang subsidiary structure means extraction has friction.

J. The Market-Cap-vs-Cash Chart

The market is paying $0.22 per dollar of book value and $0.66 per dollar of cash. The PP&E line ($3.4B at book) gets zero credit. Even a 50% writedown of fixed assets would still leave equity at roughly $4.2B — more than 3x the current market cap.

K. Valuation — P/B History

P/E and EV/EBITDA are not useful while earnings and EBITDA are negative. EV is itself negative. Price-to-book and price-to-cash are the only multiples that travel through the cycle, and the current P/B z-score of -0.66 confirms the stock is cheap relative to its own history — but the discount is tied to negative returns rather than simple neglect.

L. Peer Comparison

DQ is uniquely positioned: smallest revenue base, deepest losses per dollar of revenue, worst ROE — but the lowest P/B and the only company with a cash balance larger than its market cap. First Solar is the outlier on the other end: ~$28B market cap on $5.2B of revenue at 29% net margins, benefiting from non-Chinese supply chain status and Inflation Reduction Act credits. JinkoSolar and Canadian Solar are the closest comparators on cycle exposure, but neither has Daqo's net-cash buffer. Among pure polysilicon peers (Xinte, GCL, Tongwei), Daqo screens better on liquidity and worse on operating margin; the market is giving little credit for cash because the commodity cycle and China/ADR structure dominate the simple balance-sheet math.

M. Fair-Value Scenarios

The base case anchors on the 7-year median P/B (0.63x) and assumes book value holds at current levels — both are uncertain but neither is heroic. The bear case requires book value itself to compress by a quarter, which would mean a large polysilicon-asset impairment plus continued operating losses. The bull case requires polysilicon ASPs to materially recover, which industry forecasts suggest is more a 2027-2028 question than a 2026 one.

What the Numbers Say

The numbers confirm that Daqo is one of the lowest-cost polysilicon producers with a fortress balance sheet: $1.94B cash, no debt, current ratio 5.4x, and book value that has held flat through two years of operating losses. Even at the FY24 cash-burn rate of $935M, the company has more than two years of runway, and the burn decelerated to $161M in FY25 with operating cash flow turning positive.

The numbers contradict any simple "cheap because below cash" narrative: current gross profit, ROIC, and Q1 2026 sales volume are deeply impaired; Piotroski F-Score of 3/9 confirms fundamental weakness; the Xinjiang subsidiary structure means consolidated cash is not freely extractable; and FY2025 ASP of $5.25/kg against $6.61/kg production cost means higher volume alone cannot fix earnings.

What to watch: the polysilicon ASP-to-production-cost spread is the single metric that changes the story. A sustained move back above cost would restore free cash flow and compress the book-multiple discount fastest. Q1 2026's revenue collapse to $26.7M is the key near-term puzzle — if that quarter was inventory-cycle noise (Chinese New Year, customer destocking), the FY25 stabilization story holds; if it represents a step-function decline in demand, the runway compresses fast and the cash-vs-market-cap arbitrage will close the wrong way.